| Tag |
First Indicator |
Second Indicator |
Subfields |
| LEADER |
00000cam a2200000 a 4500 |
| 001 |
in00005772872 |
| 005 |
20260327175527.6 |
| 006 |
m o d |
| 007 |
cr |n||||||||| |
| 008 |
240131s2024 enk o 000 0 eng d |
| 040 |
|
|
|a YDX
|b eng
|c YDX
|d OPELS
|d OCLCO
|d OPELS
|d OCLCQ
|d OCLCL
|d SFB
|d N$T
|
| 020 |
|
|
|a 9780443289866
|q (electronic bk.)
|
| 020 |
|
|
|a 0443289867
|q (electronic bk.)
|
| 020 |
|
|
|z 9780443289859
|
| 020 |
|
|
|z 0443289859
|
| 035 |
|
|
|a (OCoLC)1419250636
|
| 050 |
|
4 |
|a RC280.U8
|
| 082 |
0 |
4 |
|a 616.99/466
|2 23/eng/20240305
|
| 049 |
|
|
|a TXAM
|
| 245 |
0 |
0 |
|a Strategies for overcoming chemotherapy resistance in cervical cancer
|b from molecular insights to precision solutions /
|c edited by Zodwa Dlamini.
|
| 260 |
|
|
|a London :
|b Academic Press,
|c 2024.
|
| 300 |
|
|
|a 1 online resource
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
0 |
|
|a Cancer Sensitizing Agents for Chemotherapy ;
|v 21
|
| 520 |
|
|
|a Strategies for Overcoming Chemotherapy Resistance in Cervical Cancer: From Molecular Insights to Precision Solutions, Volume 21 highlights different strategies to reverse chemotherapy resistance in cervical cancer. The book puts a strong focus on strategies to reverse chemotherapy resistance as well as strategies for early detection of the resistance, enhancing precision oncology in terms of patient care and maximizing patient management. The book also looks at virally induced resistance to chemotherapy and recommends combination therapies that can maximize the reversal of this resistance. In 10 chapters, the book not only gives an overview of cervical cancer and chemotherapy as treatment, but also investigates resistance to chemotherapy and treatment for resistance. It defines treatment mechanisms, options, and limitations to beat chemotherapy resistance and the reversal of the resistance mechanisms. It gives insights into future directions of cervical cancer treatment using epigenetic silencing, chemotherapy splicing, the involvement of MicroRNAs to chemotherapy resistance, and the application of Artificial Intelligence.
|
| 505 |
0 |
|
|a Intro -- Strategies for Overcoming Chemotherapy Resistance in Cervical Cancer: From Molecular Insights to Precision Solutions -- Copyright -- Cover Image Legend -- Aims and Scope for Series ``Cancer Sensitizing Agents for Chemotherapy´´ -- About the Series Editor -- Aims and Scope of the Volume -- About the Volume Editor -- Preface -- Contents -- Contributors -- Chapter 1: An overview of cervical cancer, chemotherapy as treatment and chemotherapy resistance -- Introduction -- Staging for cervical cancer -- The role of chemotherapy in the treatment of cervical cancer -- Mode of action: Cisplatinum -- The role of immunotherapy in the treatment of cervical cancer -- Mode of action: Immunotherapy -- Understanding the pathway for chemotherapy resistance -- DNA methylation -- Aberrant repair pathways -- Stemness -- Tumor microenvironment -- Hypoxia -- Classification of cisplatin resistance -- Pretarget resistance -- On-target resistance -- Posttarget resistance -- Off-target resistance -- Overcoming chemotherapy resistance for future management of cervical cancer -- Epigenetic regulators, and molecular therapies -- Natural products from plants, and bioactive metabolites from micro-organisms used to overcome cancer resistance -- Challenges for overcoming chemotherapy resistance in cervical cancer -- Conclusion -- References -- Chapter 2: Current treatment options and limitations for cervical cancer -- Introduction-Current approach to cervical cancer therapies -- Chemotherapy regimens and their effectiveness -- Targeted therapies and immunotherapies -- Combination therapies and clinical trials -- Limitations of current treatment options -- Conclusions -- References -- Chapter 3: Radiotherapy treatment resistance in cervical cancer -- Introduction -- Conventional clinical-pathological factors -- Patient-related factors -- Treatment-related factors.
|
| 505 |
8 |
|
|a Tumor-related factors -- Genomic markers of lymph node metastases -- Pathological tumor type and treatment resistance -- HPV and treatment resistance -- HPV subtype -- HPV viral load -- HPV integration -- Tumor hypoxia -- Genetic alterations associated with treatment response -- Limitations -- Conclusion -- References -- Chapter 4: Mechanisms of chemotherapy resistance in cervical cancer -- Background -- The tumor microenvironment (TME) as an enabling environment in CC chemoresistance -- Cancer stem cell activation -- Cancer associated fibroblasts (CAFs) and immune cells -- Tumor hypoxia in chemoresistance -- Signaling pathways and epigenetics in CC chemoresistance -- P53 pathway -- PIP3K/Akt/MAPK pathway -- EGFR pathway -- Hippo pathway -- SH3BP1 pathway -- Metabolic alterations in chemoresistance -- Combinatorial therapies in overcoming CC -- Limitations and challenges of targeting cellular and molecular mechanisms in CC chemoresistance -- Conclusions -- References -- Chapter 5: Reversal of resistance mechanisms in cervical cancer -- Introduction -- Identification of resistance mechanisms -- Reduced uptake -- Increased efflux -- Thiol-containing protein-mediated inactivation -- Increased DNA repair -- Nucleotide excision repair -- DNA mismatch repair -- Inactivation of apoptosis pathways -- Activation of EMT -- Epigenetic factors -- Stress response chaperones -- Development of novel drugs and methods to target resistance mechanisms -- Novel drugs for cervical cancer treatment -- Overcoming resistance by drug delivery mechanisms -- Liposomes -- Hydrogels -- Nanoparticles -- Repurposing of existing drugs -- Combination therapies to overcome resistance -- Conclusion -- References -- Chapter 6: HPV- and HIV-associated epigenetic silencing in cervical cancer: Targets for overcoming chemoresistance -- Introduction -- HPV, HIV, and cervical cancer.
|
| 505 |
8 |
|
|a Mechanisms of HPV/HIV interaction in cervical cancer at a molecular level -- HPV/host epigenetic modifications leading to chemoresistance in cervical cancer -- DNA methylation and chemoresistance in cervical cancer -- HPV genome methylation -- Host genome methylation -- Host methylation of apoptosis-associated genes -- Host methylation of cell cycle-associated genes -- DNA methylation of cell adhesion-associated genes -- DNA methylation of cell differentiation and proliferation-associated genes -- DNA methylation of DNA repair-associated genes -- DNA methylation of cell signaling-associated genes -- Histone acetylation -- HPV histone acetylation -- Host histone acetylation -- Potential epigenetic biomarkers for cervical cancer treatment -- Challenges and limitations of epigenetic biomarkers for cervical cancer treatment -- Conclusion and future perspective -- References -- Chapter 7: Splicing-associated chemotherapy resistance in cervical cancer: Targeting splicing signatures -- Introduction -- Alternative splicing as a normal biological process -- Dysregulated alternative splicing in cervical neoplasia and alterations in splicing regulatory factors -- Alterations in splicing factors in CC -- Alterations in hnRPNs in CC -- Splicing and chemoresistance in CC -- Deregulation of splicing factors leads to chemotherapy resistance in CC -- CeRNA networks promote chemoresistance through alternative splicing regulation -- LncRNAs splicing switch in CC chemoresistance -- CircRNAs splicing switch in CC chemoresistance -- siRNAs splicing switch in CC chemoresistance -- PiRNAs splicing switch in CC chemoresistance -- Limitations and challenges of targeting splicing signatures in alleviating CC chemoresistance -- Conclusion -- References.
|
| 505 |
8 |
|
|a Chapter 8: MicroRNA involvement in cervical cancer chemotherapy drug resistance: Restoring sensitivity to chemotherapeuti ... -- Introduction -- MicroRNAs-The potential cervical cancer treatment -- Chemotherapy resistance and sensitivity -- Application of miRNA in diagnosis and prognosis of cervical cancer -- Challenges and limitations -- Conclusion -- References -- Chapter 9: Future directions in cervical cancer treatment -- Introduction -- The roadmap to elimination of cervical cancer by 2030 -- Personalized medicine and precision oncology -- Nanocarrier and drug-based delivery systems -- Radiopharmaceutical therapy -- Computational oncology -- Artificial intelligence -- Computational intelligence -- Molecular targeted therapies -- Monoclonal antibodies -- Gene therapy -- Indigenous knowledge systems -- Identification of biomarkers for resistance -- Challenges and limitations -- Conclusion -- References -- Chapter 10: Conclusion: Overcoming chemoresistance in cervical cancer -- Index.
|
| 650 |
|
0 |
|a Cervix uteri
|x Cancer
|x Chemotherapy.
|
| 650 |
|
0 |
|a Drug resistance in cancer cells.
|
| 650 |
|
2 |
|a Drug Resistance, Neoplasm
|
| 650 |
|
6 |
|a Col de l'utérus
|x Cancer
|x Chimiothérapie.
|
| 650 |
|
6 |
|a Cellules cancéreuses
|x Résistance aux médicaments.
|
| 655 |
|
7 |
|a Electronic books.
|2 local
|
| 700 |
1 |
|
|a Dlamini, Zodwa.
|
| 710 |
2 |
|
|a ScienceDirect (Online service)
|
| 776 |
0 |
8 |
|i Print version:
|z 0443289859
|z 9780443289859
|w (OCoLC)1410103558
|
| 856 |
4 |
0 |
|u http://proxy.library.tamu.edu/login?url=https://www.sciencedirect.com/science/book/9780443289859
|z Connect to the full text of this electronic book
|t 0
|
| 955 |
|
|
|a Elsevier ScienceDirect 2026-2027
|
| 994 |
|
|
|a 92
|b TXA
|
| 999 |
f |
f |
|i 69b4d6e2-160d-41a3-bd2b-4ab9fde06e17
|s a3919a1f-ff6f-437e-8fbc-57dc649a7c1f
|t 0
|
| 952 |
f |
f |
|a Texas A&M University
|b College Station
|c Electronic Resources
|s www_evans
|d Available Online
|t 0
|e RC280.U8
|h Library of Congress classification
|
| 998 |
f |
f |
|a RC280.U8
|t 0
|l Available Online
|